Business Wire

CRYPTOS-FUND

Share
Cryptos Fund, a Quasi-ETF, Is Now Open to Investors

Cryptos Fund allows investors to gain exposure to Cryptocurrencies with reduced risk in a regulated environment.

Cryptos Fund is the brainchild of a team of leading academics, quants and security experts based in Zug, Switzerland. It is designed to passively track the CCI30 index (www.cci30.com ), an indicator of cryptocurrencies valuations and the benchmark for the sector.

Carlo Scevola, one of the fund’s principals, says: “Cryptos Fund was initially created as a private investment vehicle. I first bought Bitcoin in 2011, and when its value became substantial I wanted to diversify into other cryptocurrencies with a rigorous scientific approach. There was no suitable option available, so I created my own fund.” Cryptos Fund is also a response to heavy investor demand: “It bridges the gap between the traditional financial system and the cryptocurrencies sector. Investors need to participate in the cryptocurrency market via a regulated entity, which didn’t exist until now.”

Cryptos Fund is the only regulated fund offering a passive index tracking investment strategy on cryptocurrencies and charging no performance fees.

The CCI30 index allows for the creation of a balanced portfolio that maximizes returns while minimizing risk and volatility. The fund replicates the CCI30 index passively by investing in the components of the index (the 30 cryptocurrencies with the largest market capitalization).

Participation in the fund requires a minimum investment of USD 100,000. The fund’s annual management fee, just 0.99%, and zero performance fee make it by far the least expensive fund in the sector.

“No single investor can realistically own multiple cryptocurrencies directly. It requires time and experience to buy 30 different cryptocurrencies and keep the portfolio balanced. There are also technical and security requirements that only a dedicated professional structure can meet,” says Scevola. “Through Cryptos Fund, anyone can gain exposure to the main cryptocurrencies while reducing the volatility of the investment.”

Running an index fund requires a variety of financial and quantitative skills, along with a world-class security operation. Three partners began Cryptos Fund and are responsible for its management:

  • Igor Rivin, Professor of Mathematics at Temple University and Regius Professor at St. Andrews, one of the world’s most respected mathematicians. Recognized for his skills at the intersection of mathematics and finance; he is responsible for the research and theoretical underpinnings of Cryptos Fund.
  • Carlo Scevola, esteemed provider of legal and financial advisory services, economist and investor; Scevola is responsible for the fund organization.
  • Jeff Zorn, global security expert. Formerly the military aide to the U.S. president responsible for carrying the nuclear “football,” Zorn now advises governments and corporations on cybersecurity, threat identification and neutralization. He is responsible for all security aspects of the fund.

Baker Tilly, a full-service global accounting firm, is the fund’s appointed auditor; Trident Trust, one of the world’s top firms, is the independent administrator.

“Cryptocurrencies are not correlated with other asset classes,” professor Rivin says. “This makes Cryptos Fund the perfect vehicle for adding diversification to a portfolio. The fund can also be viewed as a safe vehicle for storing capital. Its low fees make it viable for those who want to keep their money outside the traditional banking system, while enjoying the benefits of a regulated entity and the high level of security provided by its structure.”

Operations started with a capital of $12m and institutional investors have already committed for further $100m.

Professional investors wishing to participate in Cryptos Fund can learn more at www.thecryptosfund.com .

Contact:

Cryptos Fund
Carlo Scevola, +41.445.853.445
info@thecryptosfund.com

Social Media:

https://www.facebook.com/thecryptosfund/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release

Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i

The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release

Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP

Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release

New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release

- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release

With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye